



**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

## Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis (Review)

Waters V, Ratjen F

Waters V, Ratjen F.

Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.

*Cochrane Database of Systematic Reviews* 2020, Issue 6. Art. No.: CD010004.

DOI: [10.1002/14651858.CD010004.pub5](https://doi.org/10.1002/14651858.CD010004.pub5).

[www.cochranelibrary.com](http://www.cochranelibrary.com)

---

Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis (Review)

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WILEY

---

**TABLE OF CONTENTS**

HEADER .....	1
ABSTRACT .....	1
PLAIN LANGUAGE SUMMARY .....	2
BACKGROUND .....	3
OBJECTIVES .....	4
METHODS .....	4
RESULTS .....	7
DISCUSSION .....	8
AUTHORS' CONCLUSIONS .....	8
ACKNOWLEDGEMENTS .....	9
REFERENCES .....	10
CHARACTERISTICS OF STUDIES .....	14
WHAT'S NEW .....	15
HISTORY .....	16
CONTRIBUTIONS OF AUTHORS .....	16
DECLARATIONS OF INTEREST .....	17
SOURCES OF SUPPORT .....	17
DIFFERENCES BETWEEN PROTOCOL AND REVIEW .....	17
INDEX TERMS .....	17

[Intervention Review]

# Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis

Valerie Waters<sup>1</sup>, Felix Ratjen<sup>2</sup>

<sup>1</sup>Department of Pediatrics, Division of Infectious Diseases, Hospital for Sick Children, Toronto, Canada. <sup>2</sup>Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada

**Contact address:** Valerie Waters, [valerie.waters@sickkids.ca](mailto:valerie.waters@sickkids.ca).

**Editorial group:** Cochrane Cystic Fibrosis and Genetic Disorders Group.

**Publication status and date:** New search for studies and content updated (no change to conclusions), published in Issue 6, 2020.

**Citation:** Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. *Cochrane Database of Systematic Reviews* 2020, Issue 6. Art. No.: CD010004. DOI: [10.1002/14651858.CD010004.pub5](https://doi.org/10.1002/14651858.CD010004.pub5).

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

Nontuberculous mycobacteria are mycobacteria, other than those in the *Mycobacterium tuberculosis* complex, and are commonly found in the environment. Nontuberculous mycobacteria species (most commonly *Mycobacterium avium* complex and *Mycobacterium abscessus*) are isolated from the respiratory tract of approximately 5% to 40% of individuals with cystic fibrosis; they can cause lung disease in people with cystic fibrosis leading to more a rapid decline in lung function and even death in certain circumstances. Although there are guidelines for the antimicrobial treatment of nontuberculous mycobacteria lung disease, these recommendations are not specific for people with cystic fibrosis and it is not clear which antibiotic regimen may be the most effective in the treatment of these individuals. This is an update of a previous review.

### Objectives

The objective of our review was to compare antibiotic treatment to no antibiotic treatment, or to compare different combinations of antibiotic treatment, for nontuberculous mycobacteria lung infections in people with cystic fibrosis. The primary objective was to assess the effect of treatment on lung function and pulmonary exacerbations and to quantify adverse events. The secondary objectives were to assess treatment effects on the amount of bacteria in the sputum, quality of life, mortality, nutritional parameters, hospitalizations and use of oral antibiotics.

### Search methods

We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and hand searching of journals and conference abstract books. Date of last search: 24 February 2020.

We also searched a register of ongoing trials and the reference lists of relevant articles and reviews. Date of last search: 21 March 2019.

### Selection criteria

Any randomized controlled trials comparing nontuberculous mycobacteria antibiotics to no antibiotic treatment, as well as one nontuberculous mycobacteria antibiotic regimen compared to another nontuberculous mycobacteria antibiotic regimen, in individuals with cystic fibrosis.

### Data collection and analysis

Data were not collected because in the one trial identified by the search, data specific to individuals with cystic fibrosis could not be obtained from the pharmaceutical company.

## Main results

One completed trial was identified by the searches, but data specific to individuals with cystic fibrosis could not be obtained from the pharmaceutical company.

## Authors' conclusions

This review did not find any evidence for the effectiveness of different antimicrobial treatment for nontuberculous mycobacteria lung disease in people with cystic fibrosis. Until such evidence becomes available, it is reasonable for clinicians to follow published clinical practice guidelines for the diagnosis and treatment of nodular or bronchiectatic pulmonary disease due to *Mycobacterium avium* complex or *Mycobacterium abscessus* in patients with cystic fibrosis.

## PLAIN LANGUAGE SUMMARY

### Antibiotic treatment for nontuberculous mycobacteria in people with cystic fibrosis

Nontuberculous mycobacteria are bacteria that are in the same family as tuberculosis and are commonly found in the soil and water. These bacteria can be found in the lungs of people with cystic fibrosis and can cause their lung function to worsen. Although there are guidelines on which antibiotics to use to treat lung infection due to these bacteria, these recommendations are not specific for people with cystic fibrosis. It is also not clear which are the most effective antibiotics. The main purpose of this review was to determine whether treatment with different antibiotic combinations for nontuberculous mycobacterial infection would improve lung function or decrease the frequency of chest infections in people with cystic fibrosis. We found one randomized controlled trial but it included both people with and without cystic fibrosis and we could not get the information specifically about individuals with cystic fibrosis so could not include the information in this review. Until the time when such information is available, clinicians should follow the current guidelines for the diagnosis and treatment of lung infections due to nontuberculous mycobacteria in the general population.

### Review question

We reviewed the evidence about using antibiotics to treat nontuberculous mycobacteria infection in people with cystic fibrosis.

### Background

Nontuberculous mycobacteria are bacteria that are from the same family as tuberculosis and are commonly found in the soil and water. These bacteria can be found in the lungs of people with cystic fibrosis and may cause their lung function to worsen. Although there are guidelines on which antibiotics to use to treat lung infection due to these bacteria, these recommendations are not specifically for people with cystic fibrosis. It is also not clear which antibiotics work best. The main aim of this review was to show whether or not treating nontuberculous mycobacterial infection with different combinations of antibiotics improves lung function or decreases the frequency of chest infections in people with cystic fibrosis.

### Search date

The evidence is current to: 24 February 2020.

### Study characteristics

We found one randomized controlled trial but it included both people with and without cystic fibrosis and we could not get the information specifically about individuals with cystic fibrosis so could not include the information in this review.

### Key results

Until the time when randomized controlled trial data is available for individuals with cystic fibrosis, clinicians should follow the current guidelines for the diagnosis and treatment of lung infections due to nontuberculous mycobacteria in the general population.

## BACKGROUND

### Description of the condition

Although cystic fibrosis (CF) is the most common life-shortening genetic disease in people of Northern European descent (Farrell 2018), there has been a dramatic improvement in the median survival age of individuals with CF over the past several decades (CF Foundation 2013; CF Canada 2014; Gibson 2003). As people with CF live longer, they are more likely to become colonized with environmental organisms such as nontuberculous mycobacteria (NTM).

NTM are mycobacteria other than those in the *Mycobacterium tuberculosis* complex, which includes *M tuberculosis* (Mandell 2010). They are commonly found in the environment and have been isolated from soil, water, animals, plants and birds (Falkinham 2001). Species of NTM can cause disease, such as lymphadenitis and bronchopulmonary infection, in both immunocompromised as well as immunocompetent people (Mandell 2010).

In the 1990s, NTM species began to be regularly cultured from the respiratory tract of individuals with CF around the world. Data from the Canadian and American Patient Registries estimates the prevalence of NTM infection (at least one positive culture in the prior year) between 5% and 20% of all people with CF (CFC 2016; CFF 2016). The 2010-2014 CF Patient Registry reported that 61% of NTM infections were due to *M. avium* complex, whereas the remaining 39% were due to *M. abscessus* complex (Adjemian 2018). The *M. avium* complex consists of *M. avium* and *M. intracellulare* (Mandell 2010) and the *M. abscessus* complex is generally accepted to consist of *M. abscessus*, *M. bolletii* and *M. massiliense* (Blauwendraat 2012; Tortoli 2016). People with CF who have *M. avium* complex tend to be older, have better lung function, have a higher rate of *Staphylococcus aureus* and a lower rate of *Pseudomonas aeruginosa* infection, suggesting a healthy survivorship effect in colonized individuals (Olivier 2003; Roux 2009). In contrast, *M. abscessus* infection is more prevalent than *M. avium* complex in children with CF and may lead to more deleterious clinical outcomes (Catherinot 2013; Esther 2005; Pierre-Audigier 2005; Qvist 2015). Additional factors such as geographical location and microbiological processing methods may also impact the epidemiology of NTM in people with CF. Specific decontamination procedures in the processing of CF sputum have been recommended to improve the recovery of NTM on culture and the optimal decontamination method may be different for sputum from children compared to sputum from adults (Radhakrishnan 2009; Whittier 1993). As NTM are environmental organisms, certain regions such as the mid-Atlantic and southeastern United States of America are known to have high incidence of mycobacterial disease which has been linked to the high prevalence of NTM in the soil (Brooks 1984; Satyanarayana 2011). Outbreaks of NTM pulmonary disease have also been described in CF populations in tropical regions such as Hawaii (USA) (Johnston 2016).

The presence of NTM species in the respiratory tract of people with CF signifies NTM infection, but NTM pulmonary disease causing clinical deterioration is more difficult to define in a progressive lung disease such as CF. The American Thoracic Society (ATS) in collaboration with the Infectious Diseases Society of America (IDSA) has outlined microbiological, clinical and radiological criteria for NTM disease (Griffith 2007). When examining the effects of

NTM infection on the progression of CF lung disease, evidence suggests that CF cases that meet the ATS definition of NTM disease are more likely to show progression of findings on computed tomography of the chest and have a greater decline in lung function, particularly among children (Esther 2005; Griffith 2007; Olivier 2003). In addition, infection with the *M. abscessus* species, in contrast to infection with the *M. avium* complex, leads to an increased rate of decline in lung function in people with CF compared to those uninfected with NTM, even after controlling for potential confounders (Esther 2010). There is also a report of an outbreak of *M. abscessus* complex among individuals with CF in a lung transplant center resulting in 60% mortality (Aitken 2012). Thus, although the distinction between simple infection and disease is often unclear, there are cases of NTM pulmonary disease in people with CF that cause worse clinical outcomes and require antimicrobial treatment.

### Description of the intervention

The choice of antibiotics to treat NTM pulmonary infection depends on the species of NTM isolated and is based on data primarily from people who don't have CF. Pulmonary disease caused by *M. avium* complex is usually treated with a combination of a macrolide (clarithromycin or azithromycin), rifampin or rifabutin and ethambutol (Griffith 2007). Of the known rapidly growing pathogenic mycobacteria, *M. abscessus* is the most resistant to antimicrobials and initial treatment is frequently combination therapy with clarithromycin, amikacin and either cefoxitin or imipenem. Curative therapy of *M. abscessus* lung disease is more likely to be achieved with the addition of surgical resection, but this is unlikely to be possible in a diffuse disease such as CF (Griffith 1993). Alternative therapies may be considered if in vitro susceptibility testing demonstrates resistance to these initial agents. However, in vitro susceptibility results do not always predict in vivo clinical response to therapeutic agents as clinical response depends partly on local and host defense systems (Maniu 2001). For *M. abscessus* species, there is no correlation between in vitro susceptibility results to any agent and clinical response to the treatment of pulmonary disease by these agents. Nonetheless, alternative classes of antibiotics can be considered if there is a lack of clinical response, concerns for drug toxicity or in vitro resistance noted with initial antimicrobial agents. Based on multiple studies of in vitro antimicrobial susceptibility testing of *M. abscessus* isolates, alternative antibiotics include: ciprofloxacin (susceptibility range 3% to 82%); gatifloxacin (7% to 91% susceptible); moxifloxacin (8% to 88% susceptible); linezolid (32% susceptible); and tigecycline (100% susceptible) (Gayathri 2010; Miyasaka 2007; Park 2008; Wallace 2002; Yang 2003). It is important to note that *M. abscessus* isolates may be intrinsically resistant to macrolides due to the expression of a novel *erm* gene (Nash 2009). There is some evidence to suggest that clarithromycin induces greater *erm*(41) expression and thus higher macrolide resistance than azithromycin in *M. abscessus* infection; both macrolides appear to be equally effective against *M. massiliense* species (Choi 2012; Roux 2015). In addition, people with CF may have been previously treated with antibiotics such as ciprofloxacin or azithromycin (for *P. aeruginosa*) or linezolid (for methicillin-resistant *S. aureus* (MRSA)) (Waters 2012a) and their NTM species may thus already be resistant in vitro to these agents.

### How the intervention might work

There are several case reports of people with CF with NTM infection and severe lung disease clinically responding to antimicrobial

therapy which targets the specific NTM species leading to eradication of the organism (Fauroux 1997). Antibiotic treatment of NTM pulmonary infections thus has the potential to improve lung function, reduce the frequency of pulmonary exacerbations and eliminate the bacteria from the lung in people with CF. However, there are no data on the effectiveness of early antibiotic therapy to eradicate NTM or chronic antimicrobial suppressive treatment of NTM to prevent lung function decline in CF patients. Early antibiotic therapy to eradicate NTM consists of initiation of antimicrobial treatment on first isolation of an organism in order to eliminate it from the CF lung. Chronic antimicrobial suppressive treatment refers to prolonged antimicrobial therapy to reduce the bacterial burden of the organism in the lung. Furthermore, it is not clear what is the optimal choice of antibiotics or route of antibiotic administration (oral, intravenous or inhaled) with which to treat these patients.

### Why it is important to do this review

This review is important because NTM pulmonary infections affect a significant proportion of people with CF worldwide. Data on the treatment and management of these infections is currently extrapolated from a non-CF population and its applicability to CF lung disease is unclear. It is thus necessary to determine whether there are antibiotic treatments for NTM lung infections which result in improved clinical or microbiological outcomes in people with CF.

This is an update of a previously published version of the review (Waters 2012b; Waters 2012c; Waters 2014; Waters 2016).

## OBJECTIVES

To compare antibiotic treatment to no antibiotic treatment, or to compare different combinations of antibiotic treatment, for NTM lung infections in people with CF.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

Randomized controlled trials.

#### Types of participants

Adults and children (ages 0 to 18 years) diagnosed with CF (with all levels of disease severity), confirmed with sweat test or genetic testing, or both, who have NTM pulmonary infection (defined as at least two respiratory specimens positive by culture for NTM - post hoc change) will be included. Individuals with a respiratory tract specimen that is positive on stain for acid-fast bacilli (AFB) but culture negative for NTM will not be included. Respiratory tract specimens will include sputum, lung biopsy or bronchoalveolar lavage specimens. Individuals with CF who have received a lung transplant will be excluded.

#### Types of interventions

The intervention was antibiotics to treat NTM pulmonary infections. We planned to compare NTM antibiotics to no antibiotic treatment as well as compare different NTM antibiotic regimens. Antibiotics included single or multiple antibiotics, oral, inhaled or intravenous antibiotics. Surgical interventions were excluded.

## Types of outcome measures

### Primary outcomes

1. Lung function
  - a. forced expiratory volume in one second (FEV<sub>1</sub>) (absolute values L or per cent (%) predicted or both)
  - b. forced vital capacity (FVC) (absolute values L or % predicted or both)
  - c. mid-expiratory flow (FEF<sub>25-75</sub>) (absolute values L or % predicted or both)
2. Pulmonary exacerbations, defined as an increase in respiratory symptoms requiring intravenous antibiotic therapy (Fuchs 1994) (if pulmonary exacerbations are not defined in the trial, data from that trial relating to pulmonary exacerbations will not be reported in this review)
  - a. number of pulmonary exacerbations
  - b. time between pulmonary exacerbations
  - c. time to subsequent exacerbation
3. Adverse events (proportion of participants who had to withdraw or changed therapy)
  - a. mild: transient event, no treatment change, e.g. rash, nausea, diarrhoea
  - b. moderate: treatment discontinued, e.g. nephrotoxicity, ototoxicity, hepatitis, visual impairment
  - c. severe: causing hospitalization or death

### Secondary outcomes

1. Quality of life (QoL) (as measured by a validated QoL score, i.e. CFQoL (Gee 2000), CFQ-R (Quittner 2009))
2. Mortality
3. Nutritional parameters
  - a. weight
  - b. height
  - c. body mass index (BMI)
4. Hospitalizations
  - a. number of hospitalizations
  - b. duration (days)
5. Use of oral antibiotics
6. Quantitative sputum mycobacterial culture (decrease in quantity or eradication) (post hoc change)

## Search methods for identification of studies

Trials are eligible irrespective of publication status or language.

### Electronic searches

We attempted to identify relevant trials from the Group's Cystic Fibrosis Trials Register using the terms: nontuberculous mycobacteria [NTM] AND antibiotics.

The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the *Cochrane Library*), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals - *Pediatric Pulmonology* and the *Journal of Cystic Fibrosis*. Unpublished work is identified by searching the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic

Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the Cystic Fibrosis and Genetic Disorders Group [website](#).

Date of last search of the CF Trials Register: 24 February 2020.

We also checked the National Institutes of Health (NIH) sponsored website [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and the WHO International Clinical Trials Registry ([apps.who.int/trialsearch/](http://apps.who.int/trialsearch/)) for any ongoing trials (search terms: nontuberculous mycobacteria, atypical mycobacteria, cystic fibrosis) and contacted the authors or manufacturers for potential interim results.

Date of last search of online trials registries: 16 April 2020.

### Searching other resources

We planned to check the reference lists of all trials identified for any further relevant trials.

### Data collection and analysis

One completed trial was identified by the searches, but data specific to individuals with CF could not be obtained from the pharmaceutical company so we were unable to carry out the planned analysis as detailed below. However, if in future updates of this review we are able to obtain data from any trials, we plan the following analysis.

### Selection of studies

The two authors (VW, FR) will independently apply the inclusion criteria to all potential trials. The authors will not be blinded to the trials. If a disagreement occurs, it will be resolved by discussion with a third person (Nikki Jahnke (NJ)).

### Data extraction and management

Using a data collection form, two authors (VW, FR) will independently obtain data from published reports or from trial investigators. If a disagreement occurs, the authors will resolve this by discussion with a third person (NJ). In addition to information about trial references and authors and verification of trial eligibility, the data collection form includes information about the methods of the trial (e.g. trial duration, type of trial, blinding, number of dropouts and potential confounders). When possible, the authors will extract data on sequence generation and allocation concealment. The authors will report characteristics of the trial participants including age, sex and setting of the trial on the form. Furthermore, they will also describe the intervention with regards to type of antibiotic, route of delivery, doses and length of treatment. The authors will initially analyze data from trials with different types of antibiotic, routes of delivery, doses and lengths of treatment all together and then separately in subgroup analyses (e.g. data from trials comparing oral antibiotic NTM treatments - see below). The authors will collect data for all randomized participants and attempt to collect the following data: the mean change (before and after antibiotic therapy) in FEV<sub>1</sub> and FVC, FEV<sub>25-75</sub>; the mean hospital length of stay; the time to subsequent pulmonary exacerbation; the number of adverse events; the mean QoL score after antibiotic therapy; the number of mortalities and change in weight (before and after antibiotic therapy) (see [Types of outcome measures](#) for a complete list of outcomes). For each mean value, the authors will also obtain the standard deviation (SD)

(variation from the average). For time to subsequent exacerbation, they will try to obtain log-rank estimates and Cox model estimates.

Given that NTM pulmonary infections are generally treated with more long-term antibiotics, the authors plan to measure outcomes at the following time points: one month and up to six months; six months and up to one year; and one year or longer interval. They will measure the outcome 'Time to subsequent pulmonary exacerbation' in monthly intervals after these time points. The authors will also consider outcomes measured at other time points.

### Assessment of risk of bias in included studies

The authors will assess the included trials for the following types of bias: selection bias (bias in choosing study participants); performance bias (bias in the care of study participants); attrition bias (bias in how participant loss to follow up is handled); detection bias (biased assessment of outcome); and reporting bias (bias in the reporting of study outcomes) ([Higgins 2011b](#)) using the following strategies as outlined below.

#### Assessment of generation of allocation sequences

They will assess each trial as to the generation of allocation sequences:

1. low risk of bias: if allocation sequence is suitable to prevent selection bias (i.e. random numbers table, drawing envelopes, tossing a coin, throwing dice etc);
2. high risk of bias: if allocation sequence could be related to prognosis and thus introduce selection bias (i.e. assigning participants based on case record number, date of birth, date of admission etc);
3. uncertain risk of bias: if the trial is described as randomised but the method used to generate the allocation sequence is not stated.

#### Assessment of concealment of allocation sequences

They will also assess the method used to conceal the allocation sequences in each trial:

1. low risk of bias: if participants and investigators cannot predict which group the participant will be assigned to (i.e. coded drug containers, central randomisation, numbered, sealed, opaque envelopes etc);
2. high risk of bias: if participants and investigators can predict which group the participant will be assigned to and thus introduce selection bias (i.e. open allocation schedule, non-opaque envelopes etc);
3. uncertain risk of bias: if the method of concealing the allocation sequence is not described.

#### Assessment of blinding

In order to determine the potential for performance and detection bias, the authors will assess each trial with respect to the degree of blinding:

1. the participant is blinded to participant assignment;
2. the care provider is blinded to participant assignment;
3. the investigator measuring study outcomes is blinded to participant assignment.

There will be a high risk of bias if there is no blinding with respect to one or more of the above categories. There will be a low risk of bias if the trial is blinded to all three. There will be an uncertain risk of bias if the trial does not specify the degree of blinding in each of the three categories.

#### **Incomplete outcome data**

To assess for the possibility of attrition bias, the authors will examine each trial with respect to:

1. whether or not it was stated how many participants were lost to follow-up and why they were lost to follow-up;
2. whether or not an intention-to-treat analysis was used (i.e. inclusion in the final analysis of all randomized participants into a trial in the groups to which they were randomized irrespective of what happened subsequently).

There will be a high risk of bias if an intention-to-treat analysis was not used. There will be a low risk of bias if the number and reason for loss of follow-up is specified and if an intention-to-treat analysis was used. There will be an uncertain risk of bias if the trial does not specify the above outlined information.

#### **Assessment of selective reporting**

The authors will review the included trials for selective reporting (Higgins 2011b). They will compare the original trial protocols with the published paper(s) to ensure all planned outcomes are reported. If the original trial protocols are not available, they will review the 'Methods' and 'Results' sections and use their discretion to determine if selective reporting has occurred.

#### **Assessment of other potential sources of bias**

The authors will also review the included trials for other potential sources of bias that will threaten the validity of the trial. These will include: early cessation of the trial; if the interim results affect the trial conduct; deviation from the trial protocol; inappropriate administration of a co-intervention; contamination; the use of an insensitive instrument to measure outcomes; selective reporting of subgroups; fraud; inappropriate influence of funding agencies and industry sponsorship; null bias due to the interventions being poorly delivered; or the existence of a pre-randomization of an intervention that could affect the effects of the randomized intervention (Higgins 2011a).

#### **Incorporating assessments of study validity in reviews**

The authors plan to weigh trials according to their assessed validity by using the inverse of the variance for the estimated measure of effect. If they consider there was a high risk of bias, they will investigate the effects of this with a sensitivity analysis (see below).

#### **Measures of treatment effect**

For dichotomous data, the authors will gather information on participants randomized to each treatment group (antibiotics versus no antibiotics or one antibiotic regimen versus another regimen), based on an intention-to-treat analysis, and the number of events. They plan to include interim results from individual randomized participants with CF from ongoing studies in the analysis. They will define time points for each trial outcome according to when it was measured (one to six months, six months up to one year, one year or over). They will analyze trial outcomes

separately according to these time points. The authors plan to pool the treatment effect across studies to determine a relative risk (RR) and its 95% confidence intervals (CIs) for each outcome.

For continuous data, the authors will calculate the difference between the mean (average) values (MD) of treatment effect for each group, the number in each group and the standard deviation (SD). As a summary statistic across trials, they will use the MD if the same scale is used, or the standardised mean difference (SMD) if different scales are used (e.g. QoL measurements) both with 95% CIs. For time-to-event data, most trials use Kaplan-Meier survival analysis. The authors will thus collect log-rank estimates and Cox model estimates to subsequently summarize the time-to-event data as a hazard ratio (HR) with 95% CIs (Deeks 2011; Parmar 1998).

#### **Unit of analysis issues**

The authors will include data from cluster-randomized trials if the information is available. For cluster-randomized trials, they will calculate the intra-cluster correlation coefficient (ICC) according to Donner (Donner 2001). They will also include data from cross-over trials if the information is available. Continuous data from cross-over trials will be analyzed using one of three approaches: treat the study as a parallel trial and pool the interventional periods and compare these to the pooled placebo periods; include data from the first period only and approximate a paired analysis; impute missing SDs (Higgins 2011c). Cross-over trials with dichotomous outcomes require more complicated analysis methods and for this the authors will consult with a statistician (Elbourne 2002).

#### **Dealing with missing data**

Data are often missing for participants who are lost to follow-up. In these situations, the authors will perform an available-case analysis (analyzing data for every participant for whom the outcome is obtained). They will report the percentages of participants from whom no outcome data were obtained on the data collection form. They will include data on only those whose results are known, using as a denominator the total number of people who completed the trial for the particular outcome in question. The authors will consider variation in the degree of missing data across trials as a potential source of heterogeneity.

#### **Assessment of heterogeneity**

In performing a meta-analysis, the authors will measure the variability of results between trials (heterogeneity) using the  $I^2$  method (with CIs) outlined by Higgins (Higgins 2003). The  $I^2$  statistic describes the percentage of total variation across trials that is due to heterogeneity rather than chance. It is calculated using Cochran's heterogeneity statistic and the degrees of freedom. The  $I^2$  statistic can range from 0% to 100%. A value of 0% indicates no observed heterogeneity and larger values show increasing heterogeneity. The authors will consider a value greater than 50% as substantial heterogeneity. They will also visually inspect the forest plot to assess the heterogeneity between trials.

#### **Assessment of reporting biases**

To investigate whether the review is subject to publication bias, and if they are able to include sufficient trials (at least 10), the authors will construct a funnel plot. In the absence of bias, the plot should resemble a symmetrical inverted funnel (Sterne 2011). If there is asymmetry, the authors will consider publication bias



and other reasons (such as location biases, true heterogeneity, poor methodological quality of smaller trials etc) as a potential cause.

### Data synthesis

If the authors consider that the trials are clinically similar enough to combine (e.g. studies comparing different antibiotic combinations to treat pulmonary exacerbations in participants with NTM infection), they will investigate statistical heterogeneity as outlined below. If there is no substantial heterogeneity, they will calculate the pooled effect estimates using a fixed-effect model. If they identify substantial heterogeneity ( $I^2$  statistic is greater than 50%), they will perform a random-effects meta-analysis to incorporate heterogeneity between trials.

### Subgroup analysis and investigation of heterogeneity

If the authors find substantial heterogeneity ( $I^2$  statistic is greater than 50%) (Higgins 2003), they will explore the potential causes of this (i.e. different types of antimicrobial treatment such as oral, inhaled or intravenous; different participant populations; different species of NTM etc) and if possible (if at least five trials are included for that outcome) conduct subgroup analyses of the trials. For example, trial results may vary if different types of antibiotic treatment are used (e.g. oral, inhaled or intravenous) for the treatment of pulmonary infection, or different treatment durations (e.g. six months versus one year). There may also be differences depending on whether antibiotics are used to treat a first-time infection (eradication) versus an established, chronic infection (when more than 50% of cultures are positive in the previous 12 months). Finally, there may be differing effects of antibiotic treatment of NTM pulmonary infection depending on the type of NTM species isolated (e.g. antimicrobial treatment of *M abscessus* pulmonary infections may show more of a clinical benefit than treatment of *M avium* complex infections).

### Sensitivity analysis

If the authors are able to include at least 10 trials in the review, they will perform a sensitivity analysis to determine whether the conclusions are robust to decisions made during the review process such as inclusion or exclusion of particular studies from a meta-analysis, imputing missing data or choice of a method for analysis. They will investigate whether changing which studies are included, based on their assessment of the risk of bias (initially including all trials and then excluding any with a high risk of bias) or changing our chosen statistical model (i.e. random-effects model compared to a fixed-effect model) changes the results of the review. If the sensitivity analyses do not significantly change the results presented in the review, it strengthens the confidence that can be placed in these results. The authors will present the results in an influence plot, as appropriate.

### Summary of findings tables

We will prepare summary of findings tables for each comparison included in the review. We will list population, setting, intervention and comparison and report an illustrative risk for the experimental and control intervention (Schünemann 2011). We will grade of overall quality of the body of evidence as high, moderate, low or very low using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) (Schünemann 2006). We will base our judgements on the risk of bias within the trials, their relevance to our population of interest (indirectness), unexplained

heterogeneity or inconsistency, imprecision of the results or high risk of publication bias. We will downgrade the evidence once if the risk was serious and twice if the risk was deemed to be very serious and will describe the rationale for each judgement in footnotes to each table.

For each comparison we will report the following outcomes:

- number of pulmonary exacerbations;
- change from baseline in FEV<sub>1</sub>;
- sputum mycobacterial culture conversion;
- adverse events;
- mortality;
- number of hospitalizations;
- BMI.

## RESULTS

### Description of studies

Please see the tables for further details ([Characteristics of excluded studies](#); [Characteristics of studies awaiting classification](#)).

### Results of the search

To date we have identified two published randomized controlled trials (Martiniano 2017; Olivier 2017). We also identified one ongoing study (ABATE). We have excluded one published trial and one ongoing study (ABATE; Martiniano 2017) and listed one trial as awaiting classification (Olivier 2017).

### Excluded studies

We have excluded two studies (ABATE; Martiniano 2017). One a study of intravenous gallium nitrate in people with CF has been registered but is not yet recruiting; however we have excluded this study as all participants received the same intervention, so no comparison is possible (ABATE).

The second excluded study is a comparison of an intervention in people with CF and healthy controls; all CF participants were given the same intervention (intravenous gallium nitrate) so again no comparison is possible (Martiniano 2017).

### Studies awaiting classification

One randomized controlled trial identified has been completed and published (Olivier 2017). This phase 2, randomized, double-blind controlled trial included adults (both with and without CF) who met criteria for pulmonary non-tuberculous mycobacterial disease defined by the ATS and the IDSA. Participants had received ongoing multi-drug treatment (based on ATS and IDSA guidelines) for at least six months prior to screening and had persistently positive cultures for *M avium* complex or *M abscessus*. Participants were randomized 1:1 to either liposomal amikacin for inhalation at a dose of 590 mg or placebo (empty liposomes) once daily via the PARI Investigational eFlow<sup>®</sup> Nebulizer; this regimen was added to their ongoing stable multi-drug regimen for 84 days. At the end of this period, participants could consent to receive open-label treatment with daily liposomal amikacin inhaled and their background regimen for an additional 84 days. The primary endpoint was the change from baseline to day 84 on a semi-quantitative mycobacterial growth scale. Other endpoints included sputum conversion, 6-minute walk distance and adverse events.

The modified intent-to-treat population included 89 participants (liposomal amikacin for inhalation  $n = 44$ ; placebo  $n = 45$ ); 19% of participants had CF, 64% had predominantly *M avium* complex infection and 36% had predominantly *M abscessus* infection.

### Risk of bias in included studies

No trials have yet been included in this review.

### Effects of interventions

No trials have yet been included in this review.

## DISCUSSION

### Summary of main results

We have identified one randomized controlled trial which has been completed but it included both individuals with and without CF and therefore could not yet be included in this review (Olivier 2017).

This trial of liposomal amikacin for inhalation in adults (19% of whom had CF) who met defined criteria for pulmonary NTM disease, had received ongoing multi-drug treatment for at least six months and had persistently positive cultures for *M avium* complex or *M abscessus* (Olivier 2017). In addition to their ongoing multi-drug regimen, participants were randomized to inhaled liposomal amikacin or placebo for 84 days. Although the primary endpoint of a reduction in semi-quantitative mycobacterial growth was not achieved, a greater proportion of participants in the liposomal amikacin group (32%) demonstrated sputum conversion (at least one negative mycobacterial sputum culture) than in the placebo group (9%) ( $P = 0.006$ ); however, most of those in whom sputum conversion was observed did not have CF and were infected with *M avium* complex rather than *M abscessus* infection. Those in the liposomal amikacin group also had a greater improvement in the 6-minute walk test at day 84 ( $P = 0.017$ ).

We are waiting for data for just the participants with CF before including this trial in the review.

### Overall completeness and applicability of evidence

The only identified randomized controlled trial to date was in adults only (Olivier 2017). To date, we do not have access to the data for those participants with CF, it is therefore not possible to determine the relevance of these findings to the CF population.

### Agreements and disagreements with other studies or reviews

Traditionally, antimicrobial therapy of NTM lung infection (including in people with CF) has been guided by protocols summarized in the statement endorsed by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) (Griffith 2007).

Most data are available for *M avium* complex and these recommendations are based on evidence with a highest grade of II (evidence from at least one well-designed clinical trial without randomization). The initial controlled-treatment studies were undertaken using only first-line anti-tuberculosis (TB) drugs, which have 10 to 100 times less in vitro activity against *M avium* complex than against *Mycobacterium tuberculosis*. The Research Committee of the British Thoracic Society conducted the first randomized

controlled trial of 75 participants with *M avium* complex pulmonary disease. Participants were randomized to two years of either rifampicin and ethambutol or to rifampicin, ethambutol and isoniazid (British Thoracic Society 2001; British Thoracic Society 2002). Although two thirds of enrolled participants had co-existing lung disease, it was not specified if any of them had CF. In this trial, there were fewer treatment failures or relapses with the rifampicin, ethambutol and isoniazid regimen compared to the rifampicin and ethambutol regimen (16% versus 41% respectively,  $P = 0.033$ ). However, there was a suggestion that the rifampicin, ethambutol and isoniazid regimen was associated with higher death rates overall. The advent of the newer macrolides, clarithromycin and azithromycin, was a significant advancement in the treatment of pulmonary disease due to *M avium* complex, as these drugs have good in vitro and clinical activity against *M avium* complex (Griffith 2007). Clinical studies of macrolide use with traditional anti-TB drugs have shown superior sputum conversion rates compared to historical controls (Griffith 1996; Wallace 1994; Wallace 1996). However, in a recent two-year trial of mycobacterial lung disease, clarithromycin was compared to ciprofloxacin as alternative third drugs to be added to rifampicin and ethambutol and did not demonstrate any superiority in terms of clinical outcomes in people infected with *M avium* complex (Jenkins 2008).

The other NTM species commonly isolated from the respiratory tract of people with CF is *M abscessus*. In contrast to *M avium* complex, *M abscessus* is uniformly resistant to the standard anti-tuberculous agents (Griffith 2007). There are few comparative trials of differing antimicrobial interventions for the treatment of pulmonary NTM disease due to *M abscessus*. Our search identified only one randomized, placebo-controlled trial testing liposomal amikacin for inhalation (Olivier 2017). Liposomal amikacin is an aminoglycoside drug that has been enveloped in a spherical phospholipid bilayer known as a liposome. This formulation of the drug can be delivered via inhalation to the lower airways where the lipid bilayer fuses with the bacterial cell membrane, allowing delivery of the drug into the cell (Beaulac 1997; Sachetelli 2000). The trial did not achieve its primary endpoint (reduction in semi-quantitative mycobacterial growth), but showed sputum conversion (at least one negative mycobacterial sputum culture) ( $P=0.006$ ) and improvement in 6-minute walk test ( $P=0.017$ ) at day 84 in the liposomal amikacin group compared to the placebo group. Unfortunately most participants in whom sputum conversion was observed did not have CF and were infected with *M avium* complex rather than *M abscessus* infection.

## AUTHORS' CONCLUSIONS

### Implications for practice

This review did not find any evidence from randomized controlled trials of the effectiveness of different antimicrobial treatment for nontuberculous mycobacteria (NTM) lung disease in people with cystic fibrosis (CF). Until such evidence becomes available, it is reasonable for clinicians to follow clinical practice guidelines for the management of NTM pulmonary infections in individuals with CF. The Cystic Fibrosis Foundation and the European Cystic Fibrosis Society have recently issued a consensus guideline for the screening, investigation, diagnosis and treatment of individuals with CF and NTM pulmonary disease due to *Mycobacteria avium* complex or *Mycobacteria abscessus* (Floto 2016). The antibiotic treatment regimens are generally complex due to the long

treatment durations and high frequency of associated side effects; consultation with specialists in the field is generally recommended.

### Implications for research

Given the high prevalence of NTM pulmonary infection in certain CF centers and the concern of adverse effect of *M abscessus* on lung function in young children, properly-designed and adequately-powered randomized controlled trials are needed to determine if antibiotic treatment of NTM species improves clinical outcomes, such as forced expiratory volume in one second (FEV<sub>1</sub>), in people with CF. However, properly conducted randomized controlled interventional trials are difficult to undertake in this population as there are many potential confounding variables that can affect lung function. In addition, these trials may require large sample sizes to detect significant changes in FEV<sub>1</sub>. Prospective observational studies of the diagnosis (PREDICT Trial ([NCT02073409](#))) and algorithms for the treatment (PATIENCE Trial ([NCT02419989](#))) of NTM infections in CF are also being conducted with outcome measures including microbiological eradication, lung function

and nutritional status changes and frequency of pulmonary exacerbations. Although not randomized controlled trials, such data may help guide the future management of individuals with CF with this type of infection.

### ACKNOWLEDGEMENTS

The authors thank Dr Kenneth Olivier of the National Institutes of Health and National Institute of Allergy and Infectious Diseases for additional information regarding the Arikace® trial. We would also like to thank Nikki Jahnke for her assistance in the preparation of this review.

This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.

## REFERENCES

### References to studies excluded from this review

#### ABATE {published data only}

NCT04294043. IV gallium study for patients with cystic fibrosis who have NTM (ABATE Study) (ABATE) [A Phase 1b, Multi-center Study of Intravenous (IV) Gallium Nitrate in Patients With Cystic Fibrosis (CF) Who Are Colonized With Nontuberculous Mycobacteria (NTM) (The ABATE Study)]. [www.clinicaltrials.gov/ct2/show/NCT04294043](http://www.clinicaltrials.gov/ct2/show/NCT04294043) (first posted 03 March 2020).

#### Martiniano 2017 {published data only}

Martiniano S, Wagner B, Brennan L, Wempe M, Anderson P, Nick J, et al. Pharmacokinetics of oral mac antibiotics in cystic fibrosis. *American Journal of Respiratory and Critical Care Medicine* 2017;**195**:A4842. [CENTRAL: CN-01476112] [CFGD REGISTER: PI320a] [EMBASE: 617708689]

Martiniano S, Wagner B, Brennan L, Wempe M, Anderson P, Nick J, et al. Pharmacokinetics of oral mac antibiotics in cystic fibrosis. *Journal of Cystic Fibrosis* 2017;**16 Suppl 1**:S52. [ABSTRACT NO.: EPS7.2] [CENTRAL: CN-01476112] [CFGD REGISTER: PI320b] [EMBASE: 617708689]

### References to studies awaiting assessment

#### Olivier 2017 {published data only}

Billier JA, Eagle G, McGinnis JP, Micioni L, Daley CL, Winthrop KL, et al. Efficacy of liposomal amikacin for inhalation (LAI) in achieving nontuberculous mycobacteria (NTM) culture negativity in patients whose lung infection is refractory to guideline-based therapy. *American Journal of Respiratory and Critical Care Medicine* 2015;**191 Suppl**:no pagination. [CENTRAL: 1136597] [CFGD REGISTER: PI281e] [EMBASE: 72054175]

NCT01315236. Arikace® for Nontuberculous Mycobacteria. [www.clinicaltrials.gov/ct2/show/NCT01315236?term=arikace&rank=4](http://www.clinicaltrials.gov/ct2/show/NCT01315236?term=arikace&rank=4) (accessed 01 October 2012). [CLINICALTRIALS.GOV IDENTIFIER: NCT01315236]

Olivier KN, Eagle G, McGinnis II JP, Micioni L, Daley CL, Winthrop KL, et al. Randomized, double-blind, placebo-controlled, open-label study of liposomal amikacin for inhalation (LAI) in patients with recalcitrant nontuberculous mycobacterial lung disease (NTM-LD) [abstract]. *Pediatric Pulmonology* 2014;**49 Suppl 38**:321, Abstract no: 293. [CENTRAL: 1012528] [CFGD REGISTER: PI281a]

Olivier KN, Eagle G, McGinnis JP, Micioni L, Daley CL, Winthrop KL, et al. Randomized, double-blind (DB), placebo-controlled study and open-label (OL) extension of liposomal amikacin for inhalation (LAI) in patients with refractory nontuberculous mycobacterial (NTM) lung disease (LD) [abstract]. *Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society* 2015;**14 Suppl 1**:S3, Abstract no: WS02.3. [CENTRAL: 1099086] [CFGD REGISTER: PI281b]

\* Olivier KN, Griffith DE, Eagle G, McGinnis JP, Micioni L, Liu K, et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. *American Journal*

*of Respiratory and Critical Care Medicine* 2017;**195**(6):814-23. [CFGD REGISTER: PI281g]

Olivier KN, Gupta R, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, et al. A randomized, double-blind, placebo-controlled study of liposomal Amikacin for inhalation (Arikace) in patients with recalcitrant nontuberculous mycobacterial lung disease. *American Journal of Respiratory and Critical Care Medicine* 2014;**189**:C27. [ABSTRACT NO.: A4126] [CFGD REGISTER: PI281f]

Ruoss SJ, Eagle G, McGinnis JP, Micioni L, Daley CL, Winthrop KL, et al. Analysis of functional exercise capacity (via the six-minute walk test [6MWT]) and culture negativity in patients with nontuberculous mycobacteria (NTM) lung infection refractory to guideline-based therapy treated with liposomal amikacin for inhalation (LAI). *American Journal of Respiratory and Critical Care Medicine* 2015;**191 Suppl**:no pagination. [CENTRAL: 1136596] [CFGD REGISTER: PI281d] [EMBASE: 72054176]

Winthrop KL, Eagle G, McGinnis JP, Micioni L, Daley CL, Ruoss SJ, et al. Subgroup analyses of baseline demographics and efficacy in patients with refractory nontuberculous mycobacteria (NTM) lung infection treated with liposomal amikacin for inhalation (LAI). *American Journal of Respiratory and Critical Care Medicine* 2015;**191 Suppl**:no pagination. [CENTRAL: 1136598] [CFGD REGISTER: PI281c] [EMBASE: 72054174]

### Additional references

#### Adjemian 2018

Adjemian J, Olivier KN, Prevots DR. Epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010-2014. *Annals of the American Thoracic Society* 2018;**15**(7):817-26.

#### Aitken 2012

Aitken ML, Limaye A, Pottinger P, Whimbey E, Goss CH, Tonelli MR, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. *American Journal of Respiratory and Critical Care Medicine* 2012;**185**(2):231-2. [PMID: 22246710]

#### Beaulac 1997

Beaulac C, Clement-Major S, Hawari J, Lagace J. In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition. *Journal of Microencapsulation* 1997;**14**(3):335-48.

#### Blauwendraat 2012

Blauwendraat C, Dixon GL, Hartley JC, Foweraker J, Harris KA. The use of a two-gene sequencing approach to accurately distinguish between the species within the Mycobacterium abscessus complex and Mycobacterium chelonae. *European Journal of Clinical Microbiology and Infectious Diseases* 2012;**31**(8):1847-53.

**British Thoracic Society 2001**

British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by *M avium* intracellulare, *M malmoense*, and *M xenopi* in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. *Thorax* 2001;**56**(3):167-72.

**British Thoracic Society 2002**

British Thoracic Society. Pulmonary disease caused by *Mycobacterium avium*-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment. *International Journal of Tuberculosis and Lung Disease* 2002;**6**(7):628-34.

**Brooks 1984**

Brooks RW, Parker BC, Gruft H, Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. V. Numbers in eastern United States soils and correlation with soil characteristics. *American Review of Respiratory Disease* 1984;**130**(4):630-3.

**Catherinot 2013**

Catherinot E, Roux AL, Vibet MA, Bellis G, Ravilly S, Lemonnier L, et al. *Mycobacterium avium* and *Mycobacterium abscessus* complex target distinct cystic fibrosis patient subpopulations. *Journal of Cystic Fibrosis* 2013;**12**(1):74-80.

**CF Canada 2014**

Cystic Fibrosis Canada. Patient Data Registry Report 2014. [www.cysticfibrosis.ca/assets/files/pdf/cpdr\\_reporte.pdf](http://www.cysticfibrosis.ca/assets/files/pdf/cpdr_reporte.pdf) (accessed 29 October 2012).

**CF Foundation 2013**

Cystic Fibrosis Foundation. Patient Registry Report 2013. [www.cff.org/LivingWithCF/QualityImprovement/PatientRegistryReport/#](http://www.cff.org/LivingWithCF/QualityImprovement/PatientRegistryReport/#) (accessed 29 October 2012).

**CFC 2016**

Cystic Fibrosis Canada. The Canadian cystic fibrosis registry 2016 annual data report. [www.cysticfibrosis.ca/uploads/2016%20Registry%20Annual%20Data%20Report.pdf](http://www.cysticfibrosis.ca/uploads/2016%20Registry%20Annual%20Data%20Report.pdf) (accessed 21 March 2019).

**CFF 2016**

Cystic Fibrosis Foundation. 2016 patient registry annual data report. [www.cff.org/research/researcher-resources/patient-registry/2016-patient-registry-annual-data-report.pdf](http://www.cff.org/research/researcher-resources/patient-registry/2016-patient-registry-annual-data-report.pdf) (accessed 21 March 2019).

**Choi 2012**

Choi GE, Shin SJ, Won CJ, Min KN, Oh T, Hahn MY, et al. Macrolide treatment for *Mycobacterium abscessus* and *M. massiliense* infection and inducible resistance. *American Journal of Respiratory and Critical Care Medicine* 2012 Aug 9 [Epub ahead of print].

**Deeks 2011**

Deeks J, Higgins J, Altman D. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The

Cochrane Collaboration, 2011. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org).

**Donner 2001**

Donner A, Piaggio G, Villar J. Statistical methods for the meta-analysis of cluster randomized trials. *Statistical Methods in Medical Research* 2001;**10**(5):325-38. [PMID: 11697225]

**Elbourne 2002**

Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. *International Journal of Epidemiology* 2002;**31**(1):140-9. [PMID: 11914310]

**Esther 2005**

Esther CR, Henry MM, Molina PL, Leigh MW. Nontuberculous mycobacterial infection in young children with cystic fibrosis. *Pediatric Pulmonology* 2005;**40**(1):39-44. [PMID: 15858802]

**Esther 2010**

Esther CR Jr, Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic *Mycobacterium abscessus* infection and lung function decline in cystic fibrosis. *Journal of Cystic Fibrosis* 2010;**9**(2):117-23.

**Falkinham 2001**

Falkinham JO, Norton CD, Lechevallier MW. Factors influencing numbers of *Mycobacterium avium*, *Mycobacterium intracellulare* and other *Mycobacteria* in drinking water distribution systems. *Applied and Environmental Microbiology* 2001;**67**(3):1225-31. [PMID: 11229914]

**Farrell 2018**

Farrell P, Férec C, Macek M, Frischer T, Renner S, Riss K, et al. Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis. *European Journal of Human Genetics* 2018 Aug 08 [Epub ahead of print]. [DOI: [10.1038/s41431-018-0234-z](https://doi.org/10.1038/s41431-018-0234-z)]

**Fauroux 1997**

Fauroux B, Delaisi B, Clement A, Saizou C, Moissenet D, Truffot-Pernot C, et al. *Mycobacterial lung disease in cystic fibrosis: a prospective study*. *Pediatric Infectious Disease Journal* 1997;**16**(4):354-8. [PMID: 9109135]

**Floto 2016**

Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. *Thorax* 2016;**71**(1):88-90.

**Fuchs 1994**

Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. *New England Journal of Medicine* 1994;**331**(10):637-42. [PMID: 7503821]

**Gayathri 2010**

Gayathri R, Therese KL, Deepa P, Mangai S, Madhavan HN. Antibiotic susceptibility pattern of rapidly growing mycobacteria. *Journal of Postgraduate Medicine* 2010;**56**(2):76-8. [PMID: 20622384]

**Gee 2000**

Gee L, Abbott J, Conway S, Etherington C, Webb A. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. *Thorax* 2000;**55**(11):946-54. [PMID: 11050265]

**Gibson 2003**

Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. *American Journal of Respiratory and Critical Care Medicine* 2003;**168**(8):918-51. [PMID: 14555458]

**Griffith 1993**

Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. *American Review of Respiratory Disease* 1993;**147**(5):1271-8. [PMID: 8484642]

**Griffith 1996**

Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ Jr. Azithromycin activity against *Mycobacterium avium* complex lung disease in patients who were not infected with human immunodeficiency virus. *Clinical Infectious Diseases* 1996;**23**(5):983-9.

**Griffith 2007**

Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *American Journal of Respiratory and Critical Care Medicine* 2007;**175**(4):367-416. [PMID: 17277290]

**Higgins 2003**

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**(7414):557-60. [PMID: 12958120]

**Higgins 2011a**

Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org).

**Higgins 2011b**

Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org).

**Higgins 2011c**

Higgins JPT, Deeks JJ, Altman DG on behalf of the CSMG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green

S (editors). *Cochrane Handbook of Systematic Reviews of Interventions*. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org).

**Jenkins 2008**

Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunistic mycobacterial lung diseases and an assessment of *Mycobacterium vaccae* immunotherapy. *Thorax* 2008;**63**(7):627-34.

**Johnston 2016**

Johnston DI, Chisty Z, Gross JE, Park SY. Investigation of *Mycobacterium abscessus* outbreak among cystic fibrosis patients, Hawaii 2012. *Journal of Hospital Infection* 2016;**94**(2):198-200.

**Mandell 2010**

Mandell GL, Bennett JE, Dolin R. *Principles and Practice of Infectious Diseases*. Seventh edition. Philadelphia: Churchill Livingstone Elsevier, 2010.

**Maniu 2001**

Maniu CV, Hellinger WC, Chu SY, Palmer R, Alvarez-Elcoro S. Failure of treatment for chronic *Mycobacterium abscessus* meningitis despite adequate clarithromycin levels in cerebrospinal fluid. *Clinical Infectious Diseases* 2001;**33**(5):745-8.

**Miyasaka 2007**

Miyasaka T, Kunishima H, Komatsu M, Tamai K, Mitsutake K, Kanemitsu K, et al. In vitro efficacy of imipenem in combination with six antimicrobial agents against *Mycobacterium abscessus*. *International Journal of Antimicrobial Agents* 2007;**30**(3):255-8. [PMID: 17616451]

**Nash 2009**

Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, *erm* (41), confers inducible macrolide resistance to clinical isolates of *Mycobacterium abscessus* but is absent from *Mycobacterium chelonae*. *Antimicrobial Agents and Chemotherapy* 2009;**53**(4):1367-76.

**NCT02073409**

NCT02073409. PREDICT Trial: PROspective Evaluation of NTM Disease In CysTic Fibrosis (PREDICT). [clinicaltrials.gov/ct2/show/NCT02073409](http://clinicaltrials.gov/ct2/show/NCT02073409) (first received 24 February 2014).

**NCT02419989**

NCT02419989. PATIENCE Trial: Prospective Algorithm for Treatment of NTM in Cystic Fibrosis (PATIENCE). [clinicaltrials.gov/ct2/show/NCT02419989](http://clinicaltrials.gov/ct2/show/NCT02419989) (first received: 09 December 2014).

**Olivier 2003**

Olivier KN, Weber DJ, Lee JH, Handler A, Tudor G, Molina PL, et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. *American Journal of Respiratory and Critical Care Medicine* 2003;**167**(6):828-34. [PMID: 12433669]

**Park 2008**

Park S, Kim S, Park EM, Kim H, Kwon OJ, Chang CL, et al. In vitro antimicrobial susceptibility of *Mycobacterium abscessus* in Korea. *Journal of Korean Medical Science* 2008;**23**(1):49-52. [PMID: 18303198]

**Parmar 1998**

Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Statistics in Medicine* 1998;**17**(24):2815-34. [PMID: 9921604]

**Pierre-Audigier 2005**

Pierre-Audigier C, Ferroni A, Sermet-Gaudelus I, Le Bourgeois M, Offredo C, Vu-Thien H, et al. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. *Journal of Clinical Microbiology* 2005;**43**(7):3467-70. [PMID: 16000480]

**Quittner 2009**

Quittner AL, Modi AC, Wainwright C, Otto K, Kirihaara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic *Pseudomonas aeruginosa* airway infection. *Chest* 2009;**135**(6):1610-8. [PMID: 19447923]

**Qvist 2015**

Qvist T, Gilljam M, Jönsson B, Taylor-Robinson D, Jensen-Fangel S, Wang M, et al. Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. *Journal of Cystic Fibrosis* 2015;**14**(1):46-52.

**Radhakrishnan 2009**

Radhakrishnan DK, Yau Y, Corey M, Richardson S, Chedore P, Jamieson F, et al. Non-tuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors. *Pediatric Pulmonology* 2009;**44**(11):1100-6.

**Roux 2009**

Roux AL, Catherinot E, Ripoll F, Soismier N, Macheras E, Ravilly S, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. *Journal of Clinical Microbiology* 2009;**47**(12):4124-8. [PMID: 19846643]

**Roux 2015**

Roux AL, Catherinot E, Soismier N, Heym B, Bellis G, Lemonnier L, et al. Comparing *Mycobacterium massiliense* and *Mycobacterium abscessus* lung infections in cystic fibrosis patients. *Journal of Cystic Fibrosis* 2015;**14**(1):63-9.

**Sachetelli 2000**

Sachetelli S, Khalil H, Chen T, Beaulac C, Senechal S, Lagace J. Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. *Biochimica et Biophysica Acta* 2000;**1463**(2):254-66.

**Satyanarayana 2011**

Satyanarayana G, Heysell SK, Scully KW, Houpt ER. Mycobacterial infections in a large Virginia hospital, 2001-2009. *BMC Infectious Diseases* 2011;**11**:113.

**Schünemann 2006**

Schünemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations. *Health Research Policy and Systems* 2006;**4**:21. [DOI: [10.1186/1478-4505-4-21](https://doi.org/10.1186/1478-4505-4-21)]

**Schünemann 2011**

Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH on behalf of the CA and RMG and the CSMG. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [handbook.cochrane.org](http://handbook.cochrane.org).

**Sterne 2011**

Sterne J, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org).

**Tortoli 2016**

Tortoli E, Kohl TA, Brown-Elliott BA, Trovato A, Cardoso Leao S, Garcia MJ, et al. Emended description of *Mycobacterium abscessus*, *Mycobacterium abscessus* subs. *abscessus*, *Mycobacterium abscessus* subsp. *bolletii* and designation of *Mycobacterium abscessus* subsp. *massiliense* comb. nov. *International Journal of Systematic and Evolutionary Microbiology* 2016;**66**(11):4471-9.

**Wallace 1994**

Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, et al. Initial clarithromycin monotherapy for *Mycobacterium avium*-intracellulare complex lung disease. *American Journal of Respiratory and Critical Care Medicine* 1994;**149**(5):1335-41.

**Wallace 1996**

Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary *Mycobacterium avium* complex. The first 50 patients. *American Journal of Respiratory and Critical Care Medicine* 1996;**153**(6 Pt 1):1766-72.

**Wallace 2002**

Wallace RJ Jr, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycolcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. *Antimicrobial Agents and Chemotherapy* 2002;**46**(10):3164-7. [PMID: 12234839]

**Waters 2012a**

Waters V. New treatments for emerging cystic fibrosis pathogens other than *Pseudomonas*. *Current Pharmaceutical Design* 2012;**18**(5):696-725.

**Whittier 1993**

Whittier S, Hopfer RL, Knowles MR, Gilligan PH. Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis. *Journal of Clinical Microbiology* 1993;**31**(4):861-4.

**Yang 2003**

Yang SC, Hsueh PR, Lai HC, Teng LJ, Huang LM, Chen JM, et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. *Antimicrobial Agents and Chemotherapy* 2003;**47**(6):1958-62. [PMID: 12760874]

**References to other published versions of this review**
**Waters 2012b**

Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. *Cochrane Database of Systematic Reviews* 2012, Issue 7. [DOI: [10.1002/14651858.CD010004](https://doi.org/10.1002/14651858.CD010004)]

**Waters 2012c**

Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. *Cochrane Database of Systematic Reviews* 2012, Issue 12. [DOI: [10.1002/14651858.CD010004.pub2](https://doi.org/10.1002/14651858.CD010004.pub2)]

**Waters 2014**

Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. *Cochrane Database of Systematic Reviews* 2014, Issue 12. [DOI: [10.1002/14651858.CD010004.pub3](https://doi.org/10.1002/14651858.CD010004.pub3)]

**Waters 2016**

Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. *Cochrane Database of Systematic Reviews* 2016, Issue 12. [DOI: [10.1002/14651858.CD010004.pub4](https://doi.org/10.1002/14651858.CD010004.pub4)]

\* Indicates the major publication for the study

**CHARACTERISTICS OF STUDIES**
**Characteristics of excluded studies [ordered by study ID]**

Study	Reason for exclusion
<a href="#">ABATE</a>	All participants received the same intervention (IV gallium nitrate) and no comparison is possible.
<a href="#">Martiniano 2017</a>	A comparison of people with CF and healthy controls; all the people with CF received the same intervention (oral antimycobacterial drugs for <i>Mycobacterium avium</i> complex).

CF: cystic fibrosis

IV: intravenous

**Characteristics of studies awaiting classification [ordered by study ID]**
**[Olivier 2017](#)**

Methods	Randomized (1:1), double-blind, placebo-controlled trial. Participants to visit the clinic approximately every 28 days for efficacy, safety and tolerability evaluations.
Participants	Adults (both with CF and without CF) with recalcitrant nontuberculous mycobacterial lung disease on a stable multi-drug regimen.  Eligible age range 18 to 75 years.  Estimated number to recruit: 100.
Interventions	Liposomal amikacin (Arikace <sup>®</sup> , 560 mg) for inhalation once daily using the PARI Investigational eFlow <sup>®</sup> Nebulizer (administration time approximately 13 minutes) or placebo (administration procedures, volume and administration time is the same as for Arikace <sup>®</sup> ).  Randomized treatment period planned for 84 days (Arikace <sup>®</sup> and placebo) with an option for 84 additional days of dosing with Arikace <sup>®</sup> in the open-label extension.
Outcomes	Primary outcome



**Olivier 2017** (Continued)

- Change in semi-quantitative mycobacterial culture results from baseline to end of treatment

## Secondary outcomes

- Proportion of participants with culture conversion to negative
- Time to 'rescue' anti-mycobacterial drugs
- Change from baseline in 6-minute walk distance and oxygen saturation
- Change from baseline in patient-reported outcomes
- Evaluation of safety and tolerability

## Notes

Principle investigator confirmed inclusion of participants with CF.

Supported by Insmmed Incorporated.

CF: cystic fibrosis

**WHAT'S NEW**

Date	Event	Description
10 June 2020	Amended	<p>Clarification statement added from Alan Smyth, Co-ordinating Editor on 10 June 2020: This review was found by the Cochrane Funding Arbiters, post-publication, to be noncompliant with the <a href="#">Cochrane conflict of interest policy</a>, which includes the relevant parts of the <a href="#">Cochrane Commercial Sponsorship Policy</a>. However, the Editorial Board of the Cochrane Cystic Fibrosis and Genetic Disorders Review Group believe that it is important that this empty review remains published on the Cochrane Library to reflect the current lack of evidence. This will enable researchers in countries who do not yet have funding to participate in an upcoming trial, to use this review in their application to highlight the evidence gap and to increase the likelihood of success of any funding application. The Cochrane Funding Arbiters have therefore agreed to allow this empty review to remain available for a limited time. The review will be updated by June 2022; the author team of the future update will be compliant with Cochrane policy.</p>
10 June 2020	New search has been performed	<p>A search of the Cystic Fibrosis and Genetic Disorders Review Group's Cystic Fibrosis Trials Register identified four additional references.</p> <p>Two references were to a study previously listed as 'Awaiting assessment' (<a href="#">Olivier 2017</a>). We have not yet been able to include this study as we need data for the participants relevant to this review who are a subset of the whole cohort. Data have been requested and will be included when received.</p> <p>The second study (two references) is a comparison of people with cystic fibrosis and healthy controls; this study has been excluded as all the participants with cystic fibrosis received the same treatment (<a href="#">Martiniano 2017</a>).</p> <p>A search of online trials registries identified two studies. One study was an observational study and not even listed as excluded in this review; the second study has been excluded since all participants received the same intervention and no comparison is possible (<a href="#">ABATE</a>).</p>

Date	Event	Description
10 June 2020	New citation required but conclusions have not changed	No data have been added at this update, therefore our conclusions remain the same.

## HISTORY

Protocol first published: Issue 7, 2012

Review first published: Issue 12, 2012

Date	Event	Description
15 December 2016	New search has been performed	A search of the Cochrane Cystic Fibrosis and Genetic Disorders Review Group's Cystic Fibrosis Trials Register identified four new references to a trial previously listed as 'ongoing'; this trial is now listed as 'Awaiting classification' until we are able to obtain the data specifically relating to the participants with cystic fibrosis ( <a href="#">Olivier 2017</a> ).
15 December 2016	New citation required and conclusions have changed	Since no new data have been added to the review, our conclusions have not changed.
3 December 2014	New search has been performed	A search of the Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register identified one additional reference to the trial listed in ' <a href="#">Studies awaiting classification</a> ' ( <a href="#">Olivier 2017</a> ).
3 December 2014	New citation required but conclusions have not changed	No new references have been added to this update, therefore our conclusions remain the same.

## CONTRIBUTIONS OF AUTHORS

Roles and responsibilities	
TASK	WHO WILL UNDERTAKE THE TASK?
<i>Protocol stage:</i> draft the protocol	Valerie Waters
<i>Review stage:</i> select which trials to include (2 + 1 arbiter)	Valerie Waters and Felix Ratjen (+ Nikki Jahnke)
<i>Review stage:</i> extract data from trials (2 people)	Valerie Waters and Felix Ratjen
<i>Review stage:</i> enter data into RevMan	Valerie Waters
<i>Review stage:</i> carry out the analysis	Valerie Waters and Felix Ratjen
<i>Review stage:</i> interpret the analysis	Valerie Waters and Felix Ratjen
<i>Review stage:</i> draft the final review	Valerie Waters and Felix Ratjen
<i>Update stage:</i> update the review	Valerie Waters and Felix Ratjen

## DECLARATIONS OF INTEREST

VW declares grant funding from the Cystic Fibrosis Foundation, Cystic Fibrosis Canada, Canadian Institutes of Health Research, Astrazeneca and Gilead Sciences. The funding from Gilead Sciences relates to a laboratory-based study of biofilm testing.

FR declares he has acted as a consultant to Novartis, Roche, Vertex, Boehringer Ingelheim, Bayer, Genentech. He has been paid for lectures by Genentech. FR has also received grants as PI for an early intervention study targeting *Pseudomonas* sponsored by Novartis and as PI for other grants sponsored by Vertex. While FR has received grants from Vertex, they do not produce antibiotics that would be eligible for consideration in this review.

### 10 June 2020

Clarification statement added from Alan Smyth, Co-ordinating Editor: This review was found by the Cochrane Funding Arbiters, post-publication, to be noncompliant with the [Cochrane conflict of interest policy](#), which includes the relevant parts of the [Cochrane Commercial Sponsorship Policy](#). However, the Editorial Board of the Cochrane Cystic Fibrosis and Genetic Disorders Review Group believe that it is important that this empty review remains published on the Cochrane Library to reflect the current lack of evidence. This will enable researchers in countries who do not yet have funding to participate in an upcoming trial, to use this review in their application to highlight the evidence gap and to increase the likelihood of success of any funding application. The Cochrane Funding Arbiters have therefore agreed to allow this empty review to remain available for a limited time. The review will be updated by June 2022; the author team of the future update will be compliant with Cochrane policy.

## SOURCES OF SUPPORT

### Internal sources

- No sources of support supplied

### External sources

- National Institute for Health Research, UK

This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.

## DIFFERENCES BETWEEN PROTOCOL AND REVIEW

### 1. Definition of NTM infection

In the protocol NTM infection was defined as "at least one respiratory specimen", this has been changed to the current definition which is the standard definition by the ATS of "at least two respiratory specimens positive by culture for NTM".

### 2. Secondary outcome measures

A sixth secondary outcome has been added "Quantitative sputum mycobacterial culture". This outcome was included in the original draft of the protocol, but removed following the advice of one of the peer reviewers and the contact editor. When the review authors looked at past and current ongoing RCTs for NTM lung disease, it became apparent that this is one of the main outcomes which is usually assessed and for the CF population (who may not be expected to convert their sputum), may be the most relevant. Hence the outcome has been listed again.

## INDEX TERMS

### Medical Subject Headings (MeSH)

Anti-Bacterial Agents [\*therapeutic use]; Cystic Fibrosis [\*microbiology]; Drug Therapy, Combination [methods]; Lung Diseases [\*drug therapy] [microbiology]; Mycobacterium Infections, Nontuberculous [\*drug therapy]; Nontuberculous Mycobacteria

### MeSH check words

Humans